Plectonic Biotech develops targeted molecular therapeutics utilizing proprietary Logibody technology based on DNA nanotechnology. This approach combines antibody-like specificity with the stability of DNA nanostructures for precision disease targeting. The company focuses its development pipeline on creating first-in-class therapies for oncology and autoimmune diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Current antibody-based cancer immunotherapies often lack the specificity needed to distinguish between cancerous and healthy cells, leading to on-target off-tumor reactions and severe side effects. The inability to precisely target cancer cells limits the effectiveness and tolerability of these treatments.
Solution
Plectonic Biotech leverages DNA nanotechnology to create LOGIBODY, a logic-gated nanoswitch designed to enhance the specificity of antibody immunotherapies. LOGIBODY molecules are constructed from DNA nanostructures that can be programmed to recognize unique combinations of antigens present on cancer cells. This increased specificity allows the immune system to target cancer cells in a more precise manner, reducing off-target activity on healthy tissue and minimizing associated side effects. The technology aims to improve the therapeutic window and efficacy of cancer immunotherapies.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions developing antibody-based immunotherapies for cancer treatment.
Features
- DNA-based nanoswitches that enhance the specificity of antibody-based cancer immunotherapies
- Programmable to recognize unique combinations of antigens on cancer cells
- Designed to minimize off-target effects and reduce side effects
- Utilizes DNA origami for precise nanoscale structure
- Focus on oncology and autoimmune diseases